Biotechnology internationalization in China
Biocat is holding a workshop on 25 January in Barcelona with Gao Ronghui, a consultant specializing in technology transfer, fund raising and access to the Chinese market.
By Biocat
Biocat is holding a workshop entitled Fostering internationalization (II): China on 25 January 2013 in Barcelona, featuring Gao Ronghui, a life sciences consultant with extensive experience in technology transfer, fund raising and access to the Chinese market. The workshop, which will take place in English, is geared towards executives and heads of business development at SMEs in the biotechnology and biomedicine sector, research organizations and related support bodies.
After Gao Ronghui speaks, we will open a debate among experts and executives with first-hand knowledge of this country in a roundtable entitled Challenges, opportunities and landing in the Chinese market.
- Montserrat Alavedra, Life Science Technology Advisor with ACC1Ó
- Clàudia Danesi, Asia Pacific Unit Manager at ACC1Ó
- Gao Ronghui, specialized consultant and President of G-Med Consulting
- Joan Feixas, Director of Sales and Finance at Enantia
- Marc Ramis, CEO of Tech & Business Innovation (TBI)
- Anna Roma, Executive Director of the Global Taixue consultancy in Shanghai
The roundtable will be moderated by Adela Farré, Biocat director of Communications and External Relations.
This workshop, under the framework of the European bioXclusters project, is part of a series of three events that will deal with aspects related with internationalization featuring experts in the target markets. Last April, we devoted the first session to Brazil and expect to hold a third on the United States in the first half of 2013.
China is the most populated country in the world, with more than 1,300 million inhabitants, 47% of which live in urban areas. The health sector has seen annual growth above 20% for the past 10 years. Although this booming growth is expected to slow down, the figures are well above those in the so-called developed countries.
This is a highly attractive potential market, but is not without its difficulties. Biotechnology is a strategic, preferential area under the 12th Five-Year Plan 2011-2015 and, recently, the Minister for Health announced that $11,800 millions will be earmarked for innovation in biopharma between 2016 and 2020. This investment aims to produce top-notch scientific talent and for the biotechnology industry to double the number of jobs available. Despite these positive perspectives, the cultural gap and regulatory framework for intellectual property must be taken into account when establishing trade and industrial relations.
Registration closed
Date: 25 January 2013
Time: 9 am to 1 pm
Place: ACC1Ó • Events room • Passeig de Gràcia, 129 • Barcelona (map)
Questions:
Biocat (Mamen Martí)
cmarti@biocat.cat
Tel. +34 93 310 33 30
Follow us on Twitter @bioXclusters
Presentations:
- China: life sciences industry overview and opportunities, Gao Ronghui — PDF Version | Slideshare Version
Related information:
- Reports about biotech sector in China
- Article: If you want to enter China: 'PRC' and 'JV' (Gao Ronghui, February 2013)
- Videointerview with Gao Ronghui (January 2013)
- Video conference Challenges, opportunities and landing in the Chinese market by Gao Ronghui (January 2013)
- News: Biocat trade mission to China to seek out new business opportunities (26 February 2013)
See all the news on the bioXclusters project.
| Organized by: | With collaboration from: |
|  |
